# OnCo record umoja-biopharma (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/umoja-biopharma/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "umoja-biopharma" ;
  schema:name "Umoja Biopharma"@en ;
  schema:description "In vivo CAR-T company using lentiviral vectors (VivoVec); first CD22-directed in vivo CAR-T cleared for US trials in 2026."@en ;
  schema:url <https://onco.cc/companies/umoja-biopharma/>, <https://www.umoja-biopharma.com> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://www.umoja-biopharma.com/news/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies/> ;
  onco:tag "frontier" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/all-leukemia/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/> ;
  onco:technologies <https://onco.cc/technologies/in-vivo-car-t/> ;
  onco:targets <https://onco.cc/targets/cd19/> .